These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27228176)

  • 21. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
    Lurie S; O'Quinn A
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD).
    Hammerness PG; Wilens TE; Berul CI; Elkort MS
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):219-220. PubMed ID: 18216716
    [No Abstract]   [Full Text] [Related]  

  • 23. Dexmethylphenidate (Focalin) for ADHD.
    Med Lett Drugs Ther; 2002 May; 44(1130):45-6. PubMed ID: 12011757
    [No Abstract]   [Full Text] [Related]  

  • 24. Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):157-159. PubMed ID: 34550957
    [No Abstract]   [Full Text] [Related]  

  • 25. [Methylphenidate double-blind trial: indication and performing].
    Bliznakova L; Gerstner S; Schmidt MH; Becker K
    Klin Padiatr; 2007; 219(1):9-16. PubMed ID: 17205427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [How safe are ADHD drugs?].
    Schwarz R; Muskalla B
    Kinderkrankenschwester; 2005 Oct; 24(10):437. PubMed ID: 16262203
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of stimulant medications for ADHD.
    Natl Bur Econ Res Bull Aging Health; 2014; (1):1-2. PubMed ID: 25141389
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder.
    Greenhill L; Beyer DH; Finkleson J; Shaffer D; Biederman J; Conners CK; Gillberg C; Huss M; Jensen P; Kennedy JL; Klein R; Rapoport J; Sagvolden T; Spencer T; Swanson JM; Volkow N
    J Atten Disord; 2002; 6 Suppl 1():S89-100. PubMed ID: 12685523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    Paediatr Drugs; 2006; 8(5):319-33. PubMed ID: 17037949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Questioning the treatment for ADHD.
    Breggin PR
    Science; 2001 Jan; 291(5504):595. PubMed ID: 11229399
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence.
    Godfrey J
    J Psychopharmacol; 2009 Mar; 23(2):194-205. PubMed ID: 18515459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immediate-release methylphenidate for the treatment of ADHD in adults.
    Kocher J; Adams P
    Am Fam Physician; 2015 Apr; 91(7):445-6. PubMed ID: 25884744
    [No Abstract]   [Full Text] [Related]  

  • 35. Methylphenidate (Ritalin) use and abuse.
    Crutchley A; Temlett JA
    S Afr Med J; 1999 Oct; 89(10):1076-9. PubMed ID: 10582063
    [No Abstract]   [Full Text] [Related]  

  • 36. [Methylphenidate. A drug for attention deficit disorders to be used with precaution].
    Taéron C
    Rev Infirm; 2009 Jun; (151):47-9. PubMed ID: 19579855
    [No Abstract]   [Full Text] [Related]  

  • 37. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D; Tucha O; Tucha L; Walitza S; Lange KW
    Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature.
    Kraemer M; Uekermann J; Wiltfang J; Kis B
    Clin Neuropharmacol; 2010 Jul; 33(4):204-6. PubMed ID: 20571380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L; Dondaine T; Deheul S; Marquié C; Brigadeau F; Amad A; Devos D; Danel T; Bordet R; Cottencin O; Gautier S; Ménard O
    Encephale; 2019 Feb; 45(1):74-81. PubMed ID: 30122296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.